Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 11.32 Million SEK | -77.7% |
| 2022 | 50.57 Million SEK | -53.71% |
| 2021 | 109.24 Million SEK | -11.67% |
| 2020 | 123.68 Million SEK | 10.88% |
| 2019 | 111.54 Million SEK | 10.31% |
| 2018 | 101.11 Million SEK | -2.85% |
| 2017 | 104.08 Million SEK | -20.15% |
| 2016 | 130.34 Million SEK | 106.68% |
| 2015 | 63.06 Million SEK | 133.16% |
| 2014 | 27.04 Million SEK | 49.09% |
| 2013 | 18.14 Million SEK | 5.43% |
| 2012 | 17.2 Million SEK | -3.3% |
| 2011 | 17.79 Million SEK | -1.66% |
| 2010 | 18.09 Million SEK | 31.05% |
| 2009 | 13.8 Million SEK | 600.14% |
| 2008 | -2.76 Million SEK | -153.28% |
| 2007 | 5.18 Million SEK | 195.84% |
| 2006 | -5.4 Million SEK | -129.9% |
| 2005 | 18.08 Million SEK | -24.4% |
| 2004 | 23.91 Million SEK | 22.17% |
| 2003 | 19.57 Million SEK | 32.77% |
| 2002 | 14.74 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 3 Million SEK | -60.95% |
| 2024 Q1 | -2.26 Million SEK | 62.19% |
| 2024 Q2 | 7.68 Million SEK | 439.06% |
| 2023 Q3 | 3.98 Million SEK | 149.21% |
| 2023 Q2 | -8.1 Million SEK | -134.38% |
| 2023 Q4 | -5.99 Million SEK | -250.24% |
| 2023 Q1 | 23.58 Million SEK | 487.19% |
| 2023 FY | 11.28 Million SEK | -77.7% |
| 2022 Q3 | 14.46 Million SEK | -42.69% |
| 2022 Q2 | 25.23 Million SEK | 36.48% |
| 2022 FY | 50.57 Million SEK | -53.71% |
| 2022 Q4 | -6.09 Million SEK | -142.1% |
| 2022 Q1 | 18.49 Million SEK | -45.76% |
| 2021 Q4 | 34.09 Million SEK | 42.56% |
| 2021 Q1 | 30.11 Million SEK | 1.07% |
| 2021 Q2 | 21.11 Million SEK | -29.87% |
| 2021 Q3 | 23.91 Million SEK | 13.24% |
| 2021 FY | 109.24 Million SEK | -11.67% |
| 2020 Q3 | 44.06 Million SEK | 13.37% |
| 2020 Q2 | 38.86 Million SEK | 254.64% |
| 2020 FY | 123.68 Million SEK | 10.88% |
| 2020 Q1 | 10.95 Million SEK | -68.22% |
| 2020 Q4 | 29.79 Million SEK | -32.37% |
| 2019 Q2 | 39.08 Million SEK | 245.74% |
| 2019 Q1 | 11.3 Million SEK | -63.02% |
| 2019 Q3 | 26.66 Million SEK | -31.78% |
| 2019 Q4 | 34.48 Million SEK | 29.33% |
| 2019 FY | 111.54 Million SEK | 10.31% |
| 2018 Q3 | 37.92 Million SEK | 34.36% |
| 2018 Q1 | 4.38 Million SEK | -42.59% |
| 2018 FY | 101.11 Million SEK | -2.85% |
| 2018 Q4 | 30.57 Million SEK | -19.39% |
| 2018 Q2 | 28.22 Million SEK | 543.3% |
| 2017 Q3 | 16.63 Million SEK | -46.56% |
| 2017 Q2 | 31.12 Million SEK | -44.47% |
| 2017 Q1 | 56.04 Million SEK | 28.53% |
| 2017 Q4 | 7.64 Million SEK | -54.05% |
| 2017 FY | 104.08 Million SEK | -20.15% |
| 2016 Q3 | 30.73 Million SEK | 48.76% |
| 2016 Q1 | 35.34 Million SEK | 859.57% |
| 2016 FY | 130.34 Million SEK | 106.68% |
| 2016 Q4 | 43.6 Million SEK | 41.87% |
| 2016 Q2 | 20.66 Million SEK | -41.53% |
| 2015 Q3 | 16.34 Million SEK | 4.16% |
| 2015 Q2 | 15.69 Million SEK | -42.61% |
| 2015 Q4 | 3.68 Million SEK | -77.47% |
| 2015 FY | 63.06 Million SEK | 133.16% |
| 2015 Q1 | 27.34 Million SEK | 316.38% |
| 2014 Q4 | 6.56 Million SEK | -27.24% |
| 2014 FY | 27.04 Million SEK | 49.09% |
| 2014 Q3 | 9.02 Million SEK | 69.36% |
| 2014 Q2 | 5.32 Million SEK | -13.04% |
| 2014 Q1 | 6.12 Million SEK | 100.52% |
| 2013 Q2 | 4.55 Million SEK | -24.21% |
| 2013 Q1 | 6.01 Million SEK | 131.06% |
| 2013 FY | 18.14 Million SEK | 5.43% |
| 2013 Q4 | 3.05 Million SEK | -32.42% |
| 2013 Q3 | 4.52 Million SEK | -0.72% |
| 2012 Q3 | 3.96 Million SEK | 83.02% |
| 2012 FY | 17.2 Million SEK | -3.3% |
| 2012 Q1 | 8.47 Million SEK | 1322.94% |
| 2012 Q2 | 2.16 Million SEK | -74.43% |
| 2012 Q4 | 2.6 Million SEK | -34.42% |
| 2011 Q2 | 6.26 Million SEK | -7.38% |
| 2011 Q3 | 5.46 Million SEK | -12.65% |
| 2011 Q4 | -693 Thousand SEK | -112.67% |
| 2011 FY | 17.79 Million SEK | -1.66% |
| 2011 Q1 | 6.76 Million SEK | 122.81% |
| 2010 Q1 | 3.16 Million SEK | 0.0% |
| 2010 FY | 18.09 Million SEK | 31.05% |
| 2010 Q3 | 9.22 Million SEK | 244.23% |
| 2010 Q4 | 3.03 Million SEK | -67.1% |
| 2010 Q2 | 2.67 Million SEK | -15.28% |
| 2009 FY | 13.8 Million SEK | 600.14% |
| 2008 FY | -2.76 Million SEK | -153.28% |
| 2007 FY | 5.18 Million SEK | 195.84% |
| 2006 FY | -5.4 Million SEK | -129.9% |
| 2005 FY | 18.08 Million SEK | -24.4% |
| 2004 FY | 23.91 Million SEK | 22.17% |
| 2003 FY | 19.57 Million SEK | 32.77% |
| 2002 FY | 14.74 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 185.44% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 129.585% |
| BioGaia AB (publ) | 440.9 Million SEK | 97.433% |
| Enzymatica AB (publ) | -48.06 Million SEK | 123.553% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 127.057% |
| Gabather AB (publ) | -9.47 Million SEK | 219.485% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 177.112% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 141.219% |
| Nanexa AB (publ) | -76.62 Million SEK | 114.773% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 180.409% |
| ODI Pharma AB | -1.34 Million SEK | 943.743% |
| Orexo AB (publ) | -109.5 Million SEK | 110.338% |
| Swedencare AB (publ) | 173.2 Million SEK | 93.464% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 99.757% |
| Toleranzia AB | -7.89 Million SEK | 243.455% |
| Vivesto AB | -356.71 Million SEK | 103.173% |